Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Lanreotide Autogel: A Retrospective Study in Progressive Digestive and Bronchopulmonary Neuroendocrine Neuroendocrine Tumours

Trial Profile

Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Lanreotide Autogel: A Retrospective Study in Progressive Digestive and Bronchopulmonary Neuroendocrine Neuroendocrine Tumours

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms PRELUDE
  • Sponsors Ipsen
  • Most Recent Events

    • 29 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
    • 29 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2017.
    • 30 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top